Many trials included in published meta-analyses have demonstrated that TNF-α inhibitors significantly increase the risk of tuberculosis in patients with rheumatic diseases (RA, AS, PsA) (Ai et al., 2015; Minozzi et al., 2016). Here, TNF is linked to tuberculosis.